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Abstract
Background/Aim. A high risk of bleeding in Helicobacter
pylori (H.pylori)-negative, non-steroidal anti-inflammatory
drugs (NSAID)-negative ulcers highlights the clinical im-
portance of analysis of the changing trends of peptic ulcer
disease. The aim of the study was to investigate the risk
factors for ulcer bleeding in patients with non-H. pylori in-
fection, and with no NSAIDs use. Methods. A prospective
study included patients with endoscopically diagnosed ulcer
disease. The patients were without H. pylori infection (veri-
fied by pathohistology and serology) and without exposure
to NSAIDs and proton pump inhibitors (PPI) within 4
weeks before endoscopy. After endoscopy the patients were
divided into 2 groups: the study group of 48 patients with
bleeding ulcer and the control group of 47 patients with ul-
cer, but with no bleeding. Prior to endoscopy they had
completed a questionnaire about demographics, risk factors
and habits. The platelet function, von Willebrand factor
(vWF) and blood groups were determined. Histopathologi-
cal analysis of biopsy samples were performed with a modi-
fied Sydney system. The influence of bile reflux was ana-
lyzed by Bile reflux index (BRI). Results. Age, gender, to-
bacco and alcohol use did not affect the bleeding rate. The
risk of bleeding did not depend on concomitant diseases (p
= 0.509) and exposure to stress (p = 0.944). Aspirin was
used by 16/48 (33.3%) patients with bleeding ulcer, as op-
posed to 7/47 (14.9%) patients who did not bleed (p =
0.036). Abnormal platelet function had 12/48 (25.0%) pa-
tients who bled, as opposed to 2/47 (4.3%) patients who
did not bleed (p = 0.004). Patients with BRI < 14 bled in
79.2%, and did not bleed in 57.4% of the cases (p = 0.023).
There was no statistical difference between groups in re-
gards to blood groups and range of vWF. Antrum atrophy
was found in 14/48 (29.2%) patients with bleeding ulcer
and in only 5/47 (10.6%) patients who had ulcer without
bleeding (p = 0.024). Conclusion. Abnormal platelet func-
tion, aspirin use and antrum atrophy were the risk factors
for ulcer bleeding in non-H. pylori, non- NSAIDs ulcer dis-
ease.
Key words:
peptic ulcer hemorrhage; helicobacter pylori; anti-
inflammatory agents, non-steroidal; risk factors.
Apstrakt
Uvod/Cilj. Visoki rizik od krvarenja Helicobacter pylori (H.
pylori)-negativnih i sa nesteroidnim inflamatornim lekovima
(NSAIL)-negativnih ulkusa potencirao je klini?ki zna?aj
analiziranja novih tendencija pepti?ke ulkusne bolesti. Cilj
ove studije bio je ispitati faktore rizika od nastanka krvare-
?eg ulkusa kod bolesnika bez H. pylori infekcije i bez upot-
rebe NSAIL. Metode. Prospektivna studija obuhvatala je
bolesnike sa endoskopski dijagnostikovanom ulkusnom
boleš?u. Bolesnici su bili bez H. pylori infekcije (potvr?eno
patohistološki i serološki) i bez upotrebe NSAIL i inhibitora
protonske pumpe (IPP) tokom ?etiri nedelje pre endosko-
pije. Posle endoskopije bolesnici su bili podeljeni u dve gru-
pe: studijsku grupu od 48 bolesnika sa krvare?im ulkusom i
kontrolnu grupu od 47 bolesnika sa ulkusom bez krvarenja.
Pre endoskopije bolesnici su popunjavali upitnik o demo-
grafskim podacima, faktorima rizika i navikama. Funkcija
trombocita, von Willebrand faktor (vWF) i krvne grupe is-
pitivane su, tako?e. Patohistološki su analizirani biopsijski
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uzorci po modifikovanom Sydnejskom sistemu. Uticaj bili-
jarnog refluksa analiziran je pomo?u bilijarnog refluksnog
indeksa (BRI). Rezultati. Godine, pol, pušenje i upotreba
alkohola nisu imali uticaj na stopu krvarenja. Rizik od krva-
renja nije zavisio od udruženih bolesti (p = 0,509), niti od
izloženosti stresu (p = 0,944). Aspirin je uzimalo 16/48
(33,3%) bolesnika sa krvare?im ulkusom, u porede?enju sa
7/47 (14.9%) bolesnika koji nisu krvarili (p = 0,036). Ab-
normalnu funkciju trombocita imalo je 12/48 (25,0%) bole-
snika sa krvarenjem, u pore?enju sa 2/47 (4,3%) bolesnika
koji nisu krvarili (p = 0,004). Bolesnici sa BRI < 14 krvarili
su u 79,2%, a nisu krvarili u 57,4% slu?ajeva (p = 0,023).
Nije bilo statisti?ki zna?ajne razlike izme?u dve grupe u od-
nosu na krvne grupe i nivo vWF. Antralna atrofija na?ena je
kod 14/48 (29,2%) bolesnika sa krvare?im ulkusom i kod
5/47 (10,6%) bolesnika koji su imali ulkus bez krvarenja (p
= 0,024).  Zaklju?ak. Abnormalna funkcija trombocita,
upotreba aspirina i antralna atrofija jesu faktori rizika od kr-
varenja kod H. pylori-negativne i NSAIL-negativne ulkusne
bolesti.
Klju?ne re?i:
pepti?ki ulkus, krvarenje; helicobacter pylori;
antiinflamatorici, nesteroidni; faktori rizika.
Introduction
Peptic ulcer disease has a multifactorial pathogenesis.
The discovery of Helicobacter pylori (H. pylori) infection
has dramatically changed the understanding and manage-
ment of this clinical entity. In the 1990s a number of re-
ports from around the world defined that H. pylori infection
was present in more than 90% of patients with duodenal,
and in about 85% of those with gastric ulcers 1. On the
other hand, the use of non-steroidal anti-inflammatory
drugs (NSAIDs) is the other major cause of peptic ulcers.
Several authors have found that NSAIDs were used by 25–
75% of patients with H. pylori-negative duodenal ulcers
(DU) or that NSAIDs are the most frequent identifiable
causes of non-infected DU 2.
However, the epidemiology of peptic ulcer has sig-
nificantly changed in the past decades because of the huge
effort made to eradicate H. pylori infection 3. The propor-
tion of peptic ulcers which is unrelated to NSAIDs and H.
pylori appears to be increasing. In North America, there is
good evidence that 20–40% of peptic ulcers are not associ-
ated with H. pylori or NSAIDs 3–5, whereas in other parts of
the world, the proportion of H. pylori-negative ulcers re-
mains much lower (less than 4%) 5. A study from Northern
Italy reported the prevalence of only 8% 6, 7. In Europe,
three studies from Scotland, Denmark and Italy showed a
prevalence of H. pylori-negative duodenal ulcer of 10–
15% 1. Reports from different parts of Asia show a wide
variation of its prevalence. The prevalence of H. pylori-
negative ulcer ranges from 3% in Japan to 29% in
Singapore and Pakistan. Recent reports show that the
prevalence of H. pylori-negative ulcers will also depend
upon the background prevalence of H. pylori in general
population as H. pylori-negative ulcers will not exist if
everyone has the infection 2, 5. A meta-analysis of seven
randomized double blind trials in North America found that
20% of patients with H. pylori-associated ulcers had ulcer
recurrence within 6 months, despite successful H. pylori
eradication and no reported NSAID use 3, 8.
Ulcers attributed to the use of aspirin have risen in
number, because aspirin is widely used for the prevention of
thrombotic events 9. Also, the proportion of patients taking
low-dose aspirin in combination with other antiaggregants,
such as clopidogrel is increasingly high 10.
About 25% of patients with idiopathic ulcers also have
reactive gastritis, which might be related to bile reflux or
prior NSAID use or H. pylori infection, so it might be that
mucosa does not recover fully and remains vulnerable to
other injuries.
Other etiological factors in H. pylori-negative, NSAID-
negative ulcers are poorly defined, but may include a genetic
predisposition, altered acid secretion, rapid gastric emptying,
defective mucosal defense mechanisms, psychological stress,
smoking, drinking alcohol or gender 11. A number of studies
have demonstrated a relationship between ABO blood group
and hemostasis. Indeed, a higher rate of bleeding complica-
tions has been described in patients belonging to the group
O 12, 13 and blood group O individuals are consistently over-
represented in patients with inherited bleeding disorders 12, 14.
Some authors mentioned that individuals with blood group O
have a higher risk of bleeding disorders due to low levels of
the circulating plasma protein, von Willebrand factor
(vWf) 15, 16. In a large twin study, Orstavik et al. 17 found that
66% of the total variation in plasma vWf levels was geneti-
cally determined and 30% of this genetic component was ex-
plained by ABO blood group. Plasma levels of vWf and
other coagulation factors influence risk of hemorrhage. Also,
vWf is involved in platelet adhesion and subsequent platelet
aggregation during primary haemostasis 18, 19. Another reason
for ulcer bleeding is probably the platelet dysfunction. It may
be acquired, inherited or induced by platelet inhibiting
agents, such as acetyl salicylic acid.
H. pylori-negative ulcers have been shown to have a
higher incidence of mortality and recurrent bleeding 20. Many
recent reports suggest that the pathogenesis of bleeding duo-
denal ulcer is different from that of non-complicated ulcer
disease and that other risk factors different from H. pylori are
perhaps responsible for a relatively high proportion of
bleeding ulcers 2. Study of Hung et al. 21 showed that the in-
cidence of H. pylori-negative idiopathic bleeding ulcers has
increased in recent years. According to that study, H. pylori
negative ulcers account for around 16% of bleeding peptic
ulcers.
The aim of this study, was to investigate the risk factors
for bleeding in H. pylori-negative, NSAID-negative peptic
ulcers, and to examine the factors that contribute to compli-
cated ulcers, and also to make new efforts to improve the
prevention of these conditions.
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Methods
The study was conducted in the Clinical Center of Mon-
tenegro from January 2010 to January 2012. A prospective
study included 95 consecutive patients with endoscopically di-
agnosed peptic ulcer disease who were without H. pylori in-
fection and without exposure to NSAIDs. We also excluded
patients who were taking proton pump inhibitors (PPI), antico-
agulant drugs and antiplatelet drugs except aspirin. H. pylori
status was verified by histology (two biopsy specimens taken
from the stomach antrum and two from the corpus) and serol-
ogy (antibodies to H. pylori). In cases of bleeding ulcer we
performed second look endoscopy within 72 hours from the
initial endoscopy and then took biopsies for histopathology
analyses. Blood samples were taken from all the patients
within 24 hours in order to perform serological analyses in re-
gard to the presence of antibodies to H. pylori 22. Enzyme-
linked immunoassay test (ELISA) for the quantitative detec-
tion in serum of anti-H. pylori IgG antibodies was performed
using a commercial test kit, according to instructions of the
manufacturer. The results were expressed as: reactive-positive
(IgG level > 20 IU/mL); grey zone-equivocal (IgG level: 15–
20 IU/mL) and non reactive-negative (IgG level < 15 IU/mL).
We included in the study only patients with IgG level < 15
IU/mL (non-reactive). The patients who positively responded
to the questions about NSAIDs, PPI, anticoagulant and anti-
platelet drugs (except aspirin) use less than 4 weeks before en-
doscopy were excluded from the study. The patients were di-
vided into two groups. The study group consisted of 48 pa-
tients with bleeding ulcer, while the control group of 47 pa-
tients also with ulcer, but without sings of bleeding.
Before endoscopy all the patients filled out the ques-
tionnaire on demographic data, habits (alcohol consumption
and smoking), concomitant diseases, exposure to stress dur-
ing last year, as well as on taking aspirin during the past 4
weeks. We also analyzed information related to the treatment
of H. pylori infection in the past. They also responded to
questions related to previous treatment of the diseases of up-
per gastrointestinal tract (gastritis, gastric ulcer and duodenal
ulcer) diagnosed by endoscopy over a period of 6 months
prior to inclusion in this study.
All the patients were analyzed according to gender and
age. The patients who were current smokers for at least 6
months were considered as smokers. Consuming more than 10
g of alcohol/day by women, and more than 20 g/day by men
was considered as medically relevant. The impact of concomi-
tant diseases in ulcer disease was determined by the use of in-
dividual index of co-existent diseases (ICED). The values of
ICED are 0–3, and reflect the impact of concomitant disease to
the severity of ulcer disease. The ICED score of 0 indicates that
associated diseases have no impact, score 1 indicates a mild
impact, score 2 moderate and score 3 serious impact on the oc-
currence of ulcers 23. Exposure to a stressful situation was
graded by “Holmes and Rahe stress scale”. The patients an-
swered whether in the past year they had been exposed to some
of the possibly stressful situations. By adding points for all the
exposure situations, the total number (score) indicates the im-
pact of stress on health, or occurrence of the disease. Therefore,
the score value of 300 and more indicates a risk of disease,
score value of 150–299 means that the risk of disease is inter-
mediate (reduced by 30%) and the score value of 150 or less
indicates a very low risk of disease 24. Blood groups were de-
termined by the principle of hemagglutination. The possible
impact of duodenogastric biliary reflux was assessed by calcu-
lating bile reflux index (BRI) according to Sobala et al. 25. This
index is calculated by the following formula: BRI = (7 × E) +
(3 × IM) + (4 × CI) – (6 × Hp), where E is edema in the lamina
propria, IM – intratestinal metaplasia, CI – chronic inflamma-
tion and Hp represents colonization of the stomach with H. py-
lori. The pathologists were grading each parameter from antral
biopsy specimens from 0 to 3. A value of BRI above 14 indi-
cates significant duodenogastric reflux (bile acid level grater
than 1 mmol/L, which is the upper limit of normal biliary re-
flux) with 70% sensitivity and 85%, specificity. Von Wille-
brand factor plays an important role in both primary hemostasis
by the formation of the hemostatic plug (due to its function in
platelet adhesion) and in aggregation. We used a Dade Behring
vWF Ag test kit intended for in vitro diagnostic use with Dade
Behring coagulation analyzers for the quantitative determina-
tion of vWF Ag in human plasma by immunoturbidimetry. The
normal plasma vWF level in adult population is usually in the
range of 50–160%. Detection of platelet dysfunction in citrated
human whole blood was done by the PFA - 100 system. This
system consists of an instrument and two different test car-
tridges in which the process of platelet adhesion and aggrega-
tion following a vascular injury is simulated in vitro. The colla-
gen/epinephrine (Col/EPI) test cartridge is the primary cartridge
used to detect platelet dysfunction induced by intrinsic platelet
defects, vWF, or exposure to platelet inhibiting agents. A refer-
ence range for Col/EPI is 84–160. The collagen/ADP
(Col/ADP) test cartridge is used to indicate if an abnormal re-
sult obtained with the Col/EPI test cartridge may have been
caused by the effect of aminosalicylic acid (ASA) or medica-
tion containing ASA. A reference range for Col/ADP is 68–121
s. The platelet function test is marked as normal if both Col /
EPI and Col / ADP are normal, and when any of them or both
abnormal, test is marked as abnormal.
Endoscopy procedure and histopathology examination
of mucosal biopsy samples
All endoscopies were done by an Olympus endoscope
(GIF TYPE Q 165) and biopsies were taken with standard for-
ceps. Ulcer was defined as any visual loss of mucosal integ-
rity, of a diameter greater than 5 mm, and bleeding stigmata
were classified according to the modified Forrest classifica-
tion 26. According to that classification all ulcers are divided
into those who have not bled, those that have bled and those
with bleeding during endoscopy. In cases when ulcer bleeding
required endoscopic hemostasis, it was done using either in-
jection technique with diluted epinephrine or by mechanical
device (hemoclipping). From any ulcer and surrounding mu-
cosas biopsies were taken to exclude the existence of the dis-
eases which required different therapeutic approaches, such as
malignant ulcers, Crohn’s disease, lymphoma, etc.At the same
time, two biopsies from the antrum and two from the corpus
were taken in order to histopathologically confirm the absence
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of H. pylori infection, and to additionally analyze the type of
gastritis. The modified Sydney system for classification of
gastritis was used for interpretation of biopsy samples
(Hematoxylin and Eosin staining) 27. Modified staining by
Giemsa was used for H. pylori determination.
This study was carried out in accordance with the Dec-
laration of Helsinki (2000) of the World Medical Associa-
tion. This study was approved ethically by Ethical Commit-
tee, Clinical Center of Montenegro (No 03/01-688/2, from
January 28, 2010). All the patients provided a written in-
formed consent.
All data were analyzed using SPSS, version 16.0 (SPSS
Inc, Chicago, IL, USA). Values are expressed as means or
percentages as appropriate. The ?2-test was used to analyze
the difference between the two groups. Univariate and multi-
variate logistic regression was used to analyze the risk [odds
ratio (OR) and 95% confidence interval (CI)] of developing
bleeding ulcer in patients with peptic ulcer disease. The dif-
ferences were considered significant at the level of p < 0.05.
Results
There were 48 patients with bleeding ulcer in the study
group and 47 patients with ulcer with no signs of bleeding in
the control gruop.
The demographic characteristics, habits and medical
histories with the results for the patients in the study and the
control group are shown in Table 1. Gender did not affect
bleeding. A higher incidence of bleeding peptic ulcer was
found in men but with no statistical significance (p = 0.358).
There was no difference in bleeding ulcer in relation to age
groups. There was higher incidence of bleeding ulcers
among older patients, but without statistical significance (p =
0.350). Bleeding was not affected by smoking. Alcohol con-
sumption was more frequent among patients who bled, but
the difference was not significant (p = 0.115). Risk of
bleeding from ulcer did not depend on concomitant diseases.
We had similar findings related to exposure to stress with no
significant difference between the investigated groups (p =
0.944). The previous treatment of H. pylori infection had no
effect on new bleeding ulcers. Of the patients covered by the
study, 44.8% of those who were previously treated for H.
pylori infection bled, as opposed to 55.2% of the patients
who were also previously treated, but now had ulcer without
signs of bleeding (p = 0.461). The previous treatment of gas-
tric or duodenal ulcer, did not affect future ulcer bleeding.
The history of gastritis was significantly different among the
investigated groups (p = 0.038). The logistic regression
showed that the medical history of gastritis had a protective
effect on future ulcer bleeding with relative risk for ulcer
bleeding 5 times less than in patients with no previous his-
tory of gastritis (p = 0.017). Logistic regression model (uni-
variate and multivariate) is shown in Table 2.
Table 1
Demographic sharacteristics, habits and medical history of patients
Characteristics
of the patients
Study group
n (%)
Control group
n (%)
?2-test
(p)
Total number 48 (50.5) 47 (49.5)
Gender
   men 30  (62.5) 25 (53.2) 0.358
Age, years ? 50 33 (68.8) 28 (59.6) 0.351
Medical history
   gastritis 10 (20.8) 19 (40.4) 0.038*
   gastric ulcer 5 (10.4) 6 (12.8) 0.72
   duodenal  ulcer 13 (27.1) 7 (14.9) 0.145
Smoking
   yes 22 (45.8) 22 (46.8) 0.924
Alcohol  user
  yes 24 (50.0) 16 (34.0) 0.115
Exposure to stress 24
   < 150 15 (31.3) 15 (31.9) 0.944
   150–299 22 (45.8) 20 (42.6)
   > 300 11 (22.9) 12 (25.5)
Concomitant
diseases
   yes 33 (68.7) 36 (76.6) 0.391
Previous treament
of  H. pylori
   yes 13 (44.8) 16 (55.2) 0.461
*statistically significant difference
Table 2
Logistic regression model for bleeding ulcers
Univarate Logistic Regression Multivariate Logistic RegressionCharacteristics
of the patients Exp B (95% CI) p Exp B (95% CI) p
Aspirin use 2.857 (1.048–7.786) 0.040* 1.758  (0.423–7.295) 0.437
Previous gastritis 0.388 (0.156–0.962) 0.041* 0.197 (0.052–0.746) 0.017*
Platelet dysfunction 7.500 (1.576–35.683) 0.011* 20.703 (1.724–48.643) 0.017*
Bile reflux index  ? 14 0.355 (0.144–0.878) 0.025* 0.144 (0.040–0.514) 0.003*
Antrum atrophy 3.459 (1.132–10.566) 0.029* 9.075 (1.768–46.576) 0.008*
*statistically significant difference
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The influence of aspirin and platelet function on ulcer
bleeding can be seen in Table 3. Aspirin consumption was a
significant predictive factor for bleeding in univariate logis-
tic regression, but with no significance in multivariate re-
gression model (Table 2). The platelet function was abnor-
mal in 12 (25.0%) patients with bleeding peptic ulcer, as op-
posed to 2 (4.3%) who had abnormal function of platelet and
did not bleed (?2 test; p = 0.004). At the same time, relative
risk for ulcer bleeding in the patients with platelet dysfunc-
tion was very high: 20.7 (p = 0.017) (Table 2).
The effects of blood groups and serum levels of vWF
on ulcer bleeding are presented in Table 4. Most of the pa-
tients with bleeding ulcer had blood group O (45.8%), while
blood group A was the most frequent among the patients
without ulcer bleeding (40.4%). There was no significant dif-
ference between the study and control patients regarding
blood groups (p = 0.268). The serum level of vWF did not
affect the bleeding rate, since the most of the patients in both
groups had normal level of vWF and similar proportion in
both groups had lower level of vWF (p = 0.935).
Histopathological analysis of gastric mucosa and its
impact on ulcer bleeding are shown in Table 5. Of all the
parameters of histopathological analysis of gastritis, only
atrophy of the antrum was significant predictive factor for
ulcer bleeding (?2; p = 0.024). Relative risk for ulcer
bleeding among patients with gastric antrum atrophy was
9.075 (p = 0.008). The presence of significant duodenogas-
tric bile reflux seemed to be protective against bleeding
since almost half of patients in the control group (42.6%)
and only 20.8% from the study group had BRI >14 (?2-test;
p = 0.023). Relative risk for ulcer bleeding was almost 7
times less in patients with high value of BRI (p = 0.003)
(Table 2).
Table 3
Effects of aspirin and platelet function on bleeding ulcer
Use of aspirin and
platelet function
Study group
n (%)
Control group
n (%)
?2-test
(p)
Drug
   aspirin use 16 (33.3) 7 (14.9) 0.036*
Platelet function
   abnormal 12 (25.0) 2 (4.3) 0.004*
*statistically significant difference
Table 4
The influence of blood groups and serum levels of von Willebrand factor (vWF) on ulcer bleading
Characteristics
of patients
Study group
n (%)
Control group
n (%)
?2-test
(p)
Total number 48 (50.5) 47 (49.5)
Blood groups
   A 12 (25.0) 19 (40.4)
   B 8 (16.7) 9 (19.1)
   AB 6 (12.5) 6 (12.8)
   0 22 (45.8) 13 (27.7)
0.268
(vWF)
   normal 29 (60.4) 28 (59.6)
   lower 5 (10.4) 6 (12.8)
   higher 14 (29.2) 13 (27.7)
0.935
Table 5
The influence of histopathological characteristics on ulcer bleeding
Characteristics
of the patients
Study group
n (%)
Control group
n (%)
?2-test
(p)
Total number of patients 48 (50.5) 47 (49.5) 0.05
Antrum histology (present)
   intestinal  metaplasia 13 (27.1) 18 (38.3) 0.244
   inflammation 46 (95.8) 46 (97.9) 0.570
   atrophy 14 (29.2) 5 (10.6) 0.024*
   activity 34 (70.8) 25 (53.2) 0.076
Corpus  histology (present)
   intestinal  metaplasia 10 (20.8) 12 (25.5) 0.587
   inflammation 46 (95.8) 44 (93.6) 0.629
   atrophy 13 (27.1) 13 (27.7) 0.950
   activity 24 (50.0) 30 (63.8) 0.174
Biliary reflux  index
    > 14 10 (20.8) 20 (42.6) 0.023*
*statistically significant difference
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Discussion
The prevalence of H. pylori infection is changing and
proportion of ulcers that are H. pylori-negative and NSAID-
negative seems to be increasing. Some authors observe that
these “idiopathic” peptic ulcers seem to be more resistant to
standard therapy, may be associated with more frequent
complications and these that relapse may require long-term
maintenance therapy 1, 2, 11, 28. However, as antisecretory
medications are often less effective in controlling gastric pH
in H. pylori-negative patients, it is recommended to prescribe
full doses of these drugs as maintenance therapy in this sce-
nario 2.
The incidence of bleeding ulcers is between 32 and 51
per 100 000 per year 29. Bleeding represents about 70% of all
ulcer disease complications with the highest morbidity and
mortality 30.
It seems that the prevalence of H. pylori infection is
lower among patients with bleeding ulcer than in patients
with ulcer disease without bleeding. Hung et al. 20 show that
among 638 patients with bleeding ulcers there was 18.8% H.
pylori negative patients.
One explanation for the increase in bleeding rate among
H. pylori–negative, NSAIL-negative ulcers is stress-related
ulcerogenesis due to other medical conditions 3, 31. Between
5% and 20% of patients with gastric or duodenal ulcer lack
an identifiable organic etiology and data available in studies
published worldwide suggest that psychosocial factors play a
significant role 31–33. Wong et al. 34 have shown that exposure
to a stressful situation plays an important role in the patho-
genesis of H. pylori negative ulcers, with a high risk of
rebleeding and mortality. Even though we could not find that
exposure to stress is related to bleeding peptic ulcers, we ob-
served that almost two thirds of patients with bleeding ulcer
(68.7%) had the score higher than 150, graded by “Holmes
and Rahe stress scale”.
Patients with non-NSAID and non-H. pylori ulcers are
often older, sicker and more frequently experience bleeding
episodes while in hospital 28. Xia et al. 35 have shown that
17% of duodenal ulcers were H. pylori- and NSAID-negative
and revealed that the presence of concomitant diseases was
an independent predictor for those ulcers. Some other studies
gave the same results 36–38. Na et al. 39 compared geriatric
(older than 65) and non-geriatric patients with peptic ulcer
bleeding and found that there was no difference in the inci-
dence of H. pylori negative ulcers between compared groups.
In the same time, geriatric patients with bleeding ulcers had
much higher rate of cardiovascular and pulmonary con-
comitant diseases compared to the group of non-geriatric pa-
tients.
Our results are not in accordance with these findings
especially in regard to concomitant diseases where we found
that even greater percentage of patients with other diseases
did not have ulcer bleeding. At the same time, patients older
than 50 were more frequent in our study group than in the
control group, again with no significant difference, probably
because of a small number of patients included in the present
study.
The relationship between blood group antigens and
peptic ulcer disease, especially with upper gastrointestinal
bleeding was widely evaluated in the past and one of the
studies found that the blood group O had higher frequency
in the group with bleeding ulcer than in the control group
compared to other blood groups 40. The reason for bleeding
is due to the level of the circulating plasma protein von
Willebrand factor 15. It seems that vWf levels are 25%
higher in non-O compared to group O individuals 16. An
interesting finding is that the rebleeding rate between pa-
tients with different blood groups was similar 40. At the
same time, some other studies find determination of blood
groups not being a useful tool to determine the individual
risk for gastroduodenal ulcer and ulcer bleeding 41, 42. In our
study we found that the most patients in the bleeding group
had blood group O and blood group A in the control group,
but there was no significant difference between the two
groups in regard to blood groups.
Although a number of studies have demonstrated the in-
fluence of ABO blood group on the levels of von Willebrand
factor, the nature of this association and its clinical impor-
tance is still largely unknown. A deficiency of vWF is re-
sponsible for a hemorrhagic diathesis 12. In our study low
level of vWf did not affect ulcer bleeding.
Platelet aggregation can be inhibited by aspirin.
Thrombocytopathy or impaired platelet function leads to the
commonest gastrointestinal complication – bleeding 43, 44.
Kang et al. 44 found that the most important risk factor for
bleeding peptic ulcers in H. pylori negative patients was a
history of aspirin and/or antiplatelet agent use. We have also
shown that abnormal platelet function was a significant risk
factor for ulcer bleeding. In the present study, one third of
patients who were taking aspirin had bleeding ulcer, and only
14.9% in the group of patients who were taking aspirin and
had ulcer disease without signs of bleeding. Regular or peri-
odical use of aspirin, other antiplatelet agents and/or antico-
agulant drugs is an important reason for ulcer bleeding.
After H. pylori cure, gastric acid hypersecretion is not a
risk factor for bleeding from duodenal ulcer, neither among
patients with previous bleeding episodes. However, duodenal
ulcer recurrence with bleeding may occasionally occur in
patients cured of H. pylori, even if acid output is normal 45.
Kang et al. 44 found that patients with bleeding peptic ulcer
had a higher proportion history of peptic ulcer disease. In our
study, neither previous treatment of H. pylori infection, nor
previous ulcers existence of any localization had any signifi-
cant effect on new bleeding ulcer. Mc Coll 5 reported that ul-
cers recurring after H. pylori eradication are most probably
equivalent to ulcers in patients without evidence of current or
previous infection and should be managed in the same way.
In our study we had 44.8% of patients with bleeding ulcer
who were previously treated for H. pylori infection, as well
as 55.2% of those with ulcers without bleeding and with pre-
vious H. pylori infection treatment. Eradication of H. pylori
infection did not seem to protect our patients from develop-
ing bleeding ulcer disease. It is interesting that patients with
previously treated gastritis had a less risk of ulcer bleeding in
our study.
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More studies founded that the long-standing mucosal
inflammation caused by H. pylori infection can weaken the
gastric barrier against acid or bile reflux 3. Bile and duodenal
contents have chronic noxious effects on both stomach and
esophagus. Long-term exposure, proximal reflux of duodenal
juice can damage unprotected mucosa and can cause dyspla-
sia, intestinal metaplasia and ulcers. The bile reflux index is
derived from observed changes in tissue histology and is,
thus, an important tool that can reflect mucosal changes
caused by the bile 46. In the present study we showed that the
possibility for ulcer bleeding was less if BRI was higher. It
seems that the alkaline content of bile may have a protective
effect on bleeding.
Kemppainen et al. 47 showed that antrum atrophy was
associated with a higher risk of bleeding ulcer. While H. py-
lori infection is associated with chronic active antral gastri-
tis, a lower prevalence of H. pylori is found in patients with
atrophic gastritis and intestinal metaplasia. This study also
showed that atrophy of the antrum was a significant risk
factor for ulcer bleeding.
Conclusion
The etiopathogenesis of non-H. pylori and non-NSAID
ulcers and ulcer bleeding in that setting has not been estab-
lished yet. Our results suggest that different factors were in-
volved in the etiopathogenesis of bleeding in H. pylori-
negative, NSAID-negative peptic ulcers. Relative risk for
bleeding from ulcer was significantly higher among aspirin
users, patients with abnormal platelet function and patients
with antrum atrophy. A high bile reflux index and previous
treatment of gastritis had a protective effect on ulcer bleed-
ing among patients with non-H. pylori and non-NSAID ul-
cers.
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